Native Mass Spectrometry Dissects the Structural Dynamics of an Allosteric Heterodimer of SARS-CoV-2 Nonstructural Proteins

04 September 2023, Version 1
This content is a preprint and has not undergone peer review at the time of posting.

Abstract

Structure-based drug design, which relies on precise understanding of the target protein and its interaction with the drug candidate, is dramatically expedited by advances in computational methods for candidate prediction. Yet, the accuracy needs to be improved with more structural data from high throughput experiments, which are challenging to generate, especially for dynamic and weak associations. Herein, we applied native mass spectrometry (native MS) to rapidly characterize ligand binding of an allosteric heterodimeric complex of SARS-CoV-2 two nonstructural proteins (nsp) nsp10 and nsp16 (nsp10/16). Native MS showed that the dimer is in equilibrium with monomeric states in solution. Consistent with literature, well characterized small co-substrate, RNA substrate and product bind with high specificity and affinity to the dimer but not the free monomers. Unsuccessfully designed ligands bind indiscriminately to all forms. Using neutral gas collision, the nsp16 monomer with bound co-substrate can be released from the holo dimer complex, confirming the binding to nsp16 as revealed by the crystal structure. However, an unusual migration of the endogenous zinc ions bound to nsp10 to nsp16 after collisional dissociation was observed, and can be suppressed using an alternative surface collision method at reduced precursor charge states. This highlighted the importance of careful optimization of experimental techniques. Overall, with minimal sample input (~µg), native MS can rapidly detect ligand binding affinities and locations in dynamic multi-subunit protein complexes, demonstrating the potential of an “all-in-one” native MS assay for rapid structural profiling of protein-to-AI-based compound systems to expedite drug discovery.

Keywords

native mass spectrometry
allostery
protein complex
ligand binding
structure based drug design

Supplementary materials

Title
Description
Actions
Title
Supporting Information
Description
Methods, supporting table and figures
Actions

Comments

Comments are not moderated before they are posted, but they can be removed by the site moderators if they are found to be in contravention of our Commenting Policy [opens in a new tab] - please read this policy before you post. Comments should be used for scholarly discussion of the content in question. You can find more information about how to use the commenting feature here [opens in a new tab] .
This site is protected by reCAPTCHA and the Google Privacy Policy [opens in a new tab] and Terms of Service [opens in a new tab] apply.